

# Camilla Nero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4522448/publications.pdf>

Version: 2024-02-01

35  
papers

624  
citations

516215

16  
h-index

642321

23  
g-index

35  
all docs

35  
docs citations

35  
times ranked

845  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 324.e1-324.e10.	0.7	59
2	Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 644-650.	0.3	49
3	Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1808-1815.	1.3	44
4	A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment. <i>Gynecologic Oncology</i> , 2016, 142, 19-24.	0.6	41
5	Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications. <i>Gynecologic Oncology</i> , 2018, 149, 263-269.	0.6	35
6	PTEN and Gynecological Cancers. <i>Cancers</i> , 2019, 11, 1458.	1.7	35
7	Mesenteric Lymph Node Involvement in Advanced Ovarian Cancer Patients Undergoing Rectosigmoid Resection: Prognostic Role and Clinical Considerations. <i>Annals of Surgical Oncology</i> , 2014, 21, 2369-2375.	0.7	29
8	One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer. <i>PLoS ONE</i> , 2018, 13, e0195877.	1.1	29
9	Laparoscopic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 877-883.	0.3	25
10	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.	1.7	24
11	Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 133-139.	0.3	23
12	Newly diagnosed ovarian cancer: Which first-line treatment?. <i>Cancer Treatment Reviews</i> , 2020, 91, 102111.	3.4	23
13	Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 116.	3.5	23
14	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
15	Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. <i>Cancers</i> , 2021, 13, 2089.	1.7	20
16	Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY). <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1437-1439.	1.2	19
17	Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study). <i>Scientific Reports</i> , 2020, 10, 16511.	1.6	15
18	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 425-428.	0.3	10
20	Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. <i>Annals of Surgical Oncology</i> , 2018, 25, 247-254.	0.7	10
21	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. <i>Gynecologic Oncology</i> , 2022, 165, 585-593.	0.6	10
22	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	1.9	9
23	Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment. <i>Frontiers in Oncology</i> , 2021, 11, 612450.	1.3	9
24	Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer. <i>Fertility and Sterility</i> , 2022, 117, 160-168.	0.5	6
25	PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 5200.	1.7	6
26	Further refining 2020 <sc>ESGO</sc>/<sc>ESTRO</sc>/<sc>ESP</sc> molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis. <i>Cancer</i> , 2022, 128, 2898-2907.	2.0	6
27	Robotic Splenectomy for Isolated Splenic Recurrence of Endometrial Adenocarcinoma. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 774-775.	0.3	5
28	Laparotomy approach to sentinel lymph node detection in ovarian cancer using a near-infrared fluorescent system camera with indocyanine green dye. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 712-713.	1.2	5
29	Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital. <i>Journal of Personalized Medicine</i> , 2022, 12, 3.	1.1	4
30	Minilaparoscopic Aortic Lymphadenectomy. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 546-547.	0.3	3
31	Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.	0.5	3
32	Gut microbiota and its influence on ovarian cancer carcinogenesis, anticancer therapy and surgical treatment: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103542.	2.0	3
33	Laparoscopic Management of a Small Bowel Recurrence of Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 160.	0.3	2
34	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1064-1071.	1.2	2
35	Immunotherapy in gynecological cancers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1